CYP17A1 and neoplasm: Δ4-Abiraterone has anti-tumor activity since it inhibits P450c17, HSD3B1, and is an antagonist of the AR[68], leading to the concept that abiraterone acetate may be a pro-drug and that Δ4-abiraterone is the active metabolite[69].